Lisa S Chen
Overview
Explore the profile of Lisa S Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
587
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen L, Bose P, Qiao W, Jiang Y, Wu Q, Cruz N, et al.
Leuk Lymphoma
. 2025 Feb;
:1-3.
PMID: 39921535
No abstract available.
2.
Pullarkat V, Chen L, Palmer J, Zhang J, Synold T, Buettner R, et al.
Cancer
. 2023 Oct;
130(5):727-739.
PMID: 37897709
Background: This study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of 8-chloro-adenosine (8-Cl-Ado) in patients with relapsed/refractory acute myeloid leukemia (AML). Methods: 8-Cl-Ado was administered daily for 5 days;...
3.
Aslan B, Kismali G, Iles L, Manyam G, Ayres M, Chen L, et al.
Blood Cancer J
. 2022 May;
12(5):80.
PMID: 35595730
Pirtobrutinib (LOXO-305), a reversible inhibitor of Bruton's tyrosine kinase (BTK), was designed as an alternative strategy to treat ibrutinib-resistant disease that develops due to C481 kinase domain mutations. The clinical...
4.
Hoang D, Morales C, Rodriguez I, Valerio M, Guo J, Chen M, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326597
It is known that 8-chloro-adenosine (8-Cl-Ado) is a novel RNA-directed nucleoside analog that targets leukemic stem cells (LSCs). In a phase I clinical trial with 8-Cl-Ado in patients with refractory...
5.
Teakell S, Chen L, Stellrecht C, Gandhi V
Nucleosides Nucleotides Nucleic Acids
. 2022 Mar;
41(12):1359-1374.
PMID: 35227162
8-Chloro-adenosine (8-Cl-Ado) is currently in phase I clinical trial. Activation of p53 and transactivation of p21 regulate cell fate after genotoxic insult. Using HCT-116-isogenic-cell-lines, we evaluated the role of p53/p21...
6.
Aslan B, Kismali G, Chen L, Iles L, Mahendra M, Peoples M, et al.
Blood Adv
. 2021 Aug;
5(16):3134-3146.
PMID: 34424317
Although ibrutinib improves the overall survival of patients with chronic lymphocytic leukemia (CLL), some patients still develop resistance, most commonly through point mutations affecting cysteine residue 481 (C481) in Bruton's...
7.
Groenland S, Ratain M, Chen L, Gandhi V
Am Soc Clin Oncol Educ Book
. 2021 May;
41:92-106.
PMID: 34010057
To realize the full potential of promising new anticancer drugs, it is of paramount importance to administer them at the right dose. The aim of this educational article is to...
8.
Buettner R, Truong Nguyen L, Morales C, Chen M, Wu X, Chen L, et al.
J Hematol Oncol
. 2021 Apr;
14(1):70.
PMID: 33902674
Background: BCL-2 inhibition through venetoclax (VEN) targets acute myeloid leukemia (AML) blast cells and leukemic stem cells (LSCs). Although VEN-containing regimens yield 60-70% clinical response rates, the vast majority of...
9.
Chen L, Keating M, Wierda W, Gandhi V
Leuk Lymphoma
. 2019 Jun;
60(12):3063-3066.
PMID: 31161836
No abstract available.
10.
Buettner R, Truong Nguyen L, Kumar B, Morales C, Liu C, Chen L, et al.
J Cell Physiol
. 2019 Feb;
234(9):16295-16303.
PMID: 30770553
Nucleoside analogs represent the backbone of several distinct chemotherapy regimens for acute myeloid leukemia (AML) and combination with tyrosine kinase inhibitors has improved survival of AML patients, including those harboring...